Immune Response to Racotumomab in a Child with Relapsed Neuroblastoma.
Frontiers in oncology(2012)
摘要
Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside.
更多查看译文
关键词
immunotherapy,monoclonal antibodies,neuroblastoma,ganglioside,racotumomab
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要